Florida Urologist opportunity. Stellar doctor needed to join three BC Urologists. The preferred candidate must have Laparoscopic and/or Robotic Training. Group is offering a salary,production bonus, a...
The average mortality rate of idiopathic pulmonary fibrosis (IPF) is estimated to be 50.8 per 1,000,000 people per year. The mortality rate is now higher than recent mortality rates for a number of malignancies. Although IPF should no longer be considered a rare disease, there is no established treatment that definitely improves its outcome. Furthermore, about 10% of IPF causes a very rapid progression called "acute exacerbation".
VX-770 Based on data presented to date, Vertex intends to work with global regulatory authorities on the design of a registration program for VX-770 which, if agreed upon, could begin in the first half of 2009.
Market pressures may have more influence on clinical practice than laboratory guidelines: That's one conclusion of a Center survey, which found that guidelines for cystic fibrosis (CF) carrier screening have only been partially adopted.
If you are afflicted with a genetic disease -- or at risk of developing one -- how do you handle it? Do you tell your loved ones? What is the best way to cope? If your loved one has a genetic disorder, how do you best adapt? New research funded by the National Human Genome Research Inst
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the presentation of additional data from TIGER-1, the Company's first Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis, at the 22nd Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, FL on October 23 - 25, 2008.
Researchers at National Jewish Health have identified a simple gene-based blood test that more accurately and quickly measures cystic fibrosis patients' response to therapy than current tests. The test, a measure of inflammatory gene expression, could improve patient care and help clear a backlog of promising medications now hung up in clinical trials.
